Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2026-06-17 19:51:47 ET · period of report 2026-06-15 · accession 0001610717-26-000230 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-17 19:51 | 2026-06-15+ | RVMD | Horn Margaret A | COO | M - OptEx | $30.82 | +90.0K | 184.2K | +95% | +$2.77M |
| DMT | 2026-06-17 19:51 | 2025-06-16+ | RVMD | Horn Margaret A | COO | S - Sale+OE | $160.00 | -93.6K | 154.6K | -38% | -$14.97M |
| DMT | 2026-06-17 19:51 | 2026-06-15+ | RVMD | Horn Margaret A | COO | M - OptEx | $0.00 | -90.0K | 114.3K | -44% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | M | A | 15,546 | $40.74 | 173,768 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F2) Includes 73,050 restricted stock units ("RSUs"). |
| 2 | Common | Common Stock | 2026-06-15 | M | A | 44,854 | $29.80 | 218,622 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F2) Includes 73,050 restricted stock units ("RSUs"). |
| 3 | Common | Common Stock | 2026-06-15 | S | D | 60,400 | $160.17 | 158,222 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F3) This transaction was executed in multiple trades in prices ranging from $160.00 to $160.3550, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 73,050 restricted stock units ("RSUs"). |
| 4 | Common | Common Stock | 2025-06-16 | S | D | 3,575 | $156.12 | 154,647 | D | — | — | (F4) Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of RSUs after July 15, 2023. (F5) This transaction was executed in multiple trades in prices ranging from $156.1105 to $156.8250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F6) Includes 66,201 RSUs. |
| 5 | Common | Common Stock | 2026-06-17 | M | A | 573 | $40.74 | 155,220 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F6) Includes 66,201 RSUs. |
| 6 | Common | Common Stock | 2026-06-17 | M | A | 3,302 | $29.80 | 158,522 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F6) Includes 66,201 RSUs. |
| 7 | Common | Common Stock | 2026-06-17 | M | A | 25,725 | $26.50 | 184,247 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F6) Includes 66,201 RSUs. |
| 8 | Common | Common Stock | 2026-06-17 | S | D | 29,600 | $160.12 | 154,647 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F7) This transaction was executed in multiple trades in prices ranging from $160.00 to $160.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F6) Includes 66,201 RSUs. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-06-15 | M | D | 15,546 | $0.00 | 75,648 | D | $40.74 · — to 2035-02-28 | 15,546 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F8) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
| 10 | Derivative | Stock Option (Right to Buy) | 2026-06-15 | M | D | 44,854 | $0.00 | 75,052 | D | $29.80 · — to 2034-02-28 | 44,854 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F9) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
| 11 | Derivative | Stock Option (Right to Buy) | 2026-06-17 | M | D | 573 | $0.00 | 75,075 | D | $40.74 · — to 2035-02-28 | 573 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F8) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
| 12 | Derivative | Stock Option (Right to Buy) | 2026-06-17 | M | D | 3,302 | $0.00 | 71,750 | D | $29.80 · — to 2034-02-28 | 3,302 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F9) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
| 13 | Derivative | Stock Option (Right to Buy) | 2026-06-17 | M | D | 25,725 | $0.00 | 114,275 | D | $26.50 · — to 2033-02-28 | 25,725 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. (F10) One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |